This is therefore a comparing of the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation in Krystal Biotech Inc. (NASDAQ:KRYS) and Forward Pharma A/S (NASDAQ:FWP). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech Inc.	N/A	0.00	10.89M	-0.82	0.00
Forward Pharma A/S	N/A	0.00	29.41M	-0.28	0.00

Table 1 demonstrates Krystal Biotech Inc. and Forward Pharma A/S’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
Krystal Biotech Inc.	0.00%	-17.6%	-17.3%
Forward Pharma A/S	0.00%	-7.8%	-6.5%

Liquidity

Krystal Biotech Inc.’s Current Ratio is 27.6 while its Quick Ratio is 27.6. On the competitive side is, Forward Pharma A/S which has a 17.2 Current Ratio and a 17.2 Quick Ratio. Krystal Biotech Inc. is better positioned to pay off short and long-term obligations compared to Forward Pharma A/S.

Institutional and Insider Ownership

Institutional investors held 43% of Krystal Biotech Inc. shares and 20.9% of Forward Pharma A/S shares. Krystal Biotech Inc.’s share held by insiders are 28%.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Krystal Biotech Inc.	-2.87%	-4.84%	-7.56%	33.09%	118.25%	5.87%
Forward Pharma A/S	0.47%	28.38%	26.05%	-53.78%	-51.35%	77.76%

For the past year Krystal Biotech Inc. has weaker performance than Forward Pharma A/S

Summary

Forward Pharma A/S beats on 4 of the 6 factors Krystal Biotech Inc.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The companyÂ’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. It also develops KB104 that is in preclinical studies to treat Netherton syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.